Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Joshua W. D. Tobin, Anna Crothers, Ti Eric Ma, Peter Mollee, Maher K. Gandhi, Paul Scuffham & Greg Hapgood. (2021) A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia & Lymphoma 62:14, pages 3484-3492.
Read now
Read now
Ziyan Chen, Yue Cheng, David DeRemer & Vakaramoko Diaby. (2021) Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 923-941.
Read now
Read now
Michele R Wilson, Ismail Azzabi Zouraq, Helene Chevrou-Severac, Ross Selby & Matthew C Kerrigan. (2017) Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. ClinicoEconomics and Outcomes Research 9, pages 641-652.
Read now
Read now
M. C. Cheung, A. Prica, J. Graczyk, R. Buckstein & K. K. W. Chan. (2016) Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. Leukemia & Lymphoma 57:8, pages 1865-1875.
Read now
Read now
Natalia Olchanski, Yue Zhong, Joshua T. Cohen, Cayla Saret, Mohan Bala & Peter J. Neumann. (2015) The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 931-940.
Read now
Read now
Julieta F Scalo & Karen L Rascati. (2014) Trends and issues in oncology costs. Expert Review of Pharmacoeconomics & Outcomes Research 14:1, pages 35-44.
Read now
Read now
Karissa M Johnston, Corneliu Bolbocean, Joseph Connors & Stuart Peacock. (2012) Cost–effectiveness of rituximab in follicular lymphoma. Expert Review of Pharmacoeconomics & Outcomes Research 12:5, pages 569-577.
Read now
Read now
Roy Beveridge, Sacha Satram-Hoang, Kavita Sail, Joseph Darragh, Clara Chen, Michael Forsyth & Carolina Reyes. (2011) Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leukemia & Lymphoma 52:11, pages 2117-2123.
Read now
Read now
Firas Badin & John Hayslip. (2010) Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. ClinicoEconomics and Outcomes Research 2, pages 37-45.
Read now
Read now
Articles from other publishers (27)
Vasiliki Iliadou & Kostas Athanasakis. (2023) Sensitivity Analysis in Economic Evaluations of Immuno-Oncology Drugs: A Systematic Literature Review. Value in Health Regional Issues 37, pages 23-32.
Crossref
Crossref
Ting Zhou, Yanan Sheng, Haijing Guan, Rui Meng & Zijing Wang. (2021) Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China. Frontiers in Public Health 9.
Crossref
Crossref
Ting Zhou, Yanan Sheng & Haijing Guan. (2021) Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China. Advances in Therapy 38:8, pages 4233-4245.
Crossref
Crossref
Neerav Monga, Jamie Garside, Binu Gurung, Joan Quigley, Peter O’Donovan, Christoph Tapprich, Loretta Nastoupil, Catherine Thieblemont & Christina Loefgren. (2020) Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. PharmacoEconomics - Open 4:4, pages 575-591.
Crossref
Crossref
Amanda Hansson-Hedblom, Chrissy Almond, Fredrik Borgström, Indeg Sly, Dana Enkusson, Anders Troelsgaard Buchholt & Linda Karlsson. (2018) Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Han-I Wang, Eve Roman, Simon Crouch, Eline Aas, Cathy Burton, Russell Patmore & Alexandra Smith. (2018) A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data. Value in Health 21:10, pages 1176-1185.
Crossref
Crossref
Bernd Markus Lange. 2018. Biotechnology of Natural Products. Biotechnology of Natural Products
189
218
.
H Park, YS Kyung & G Lee. (2015) Urinary uroplakin expression in cyclophosphamide-induced rat cystitis model. Human & Experimental Toxicology 35:6, pages 613-622.
Crossref
Crossref
Karen Lien, Matthew C. Cheung & Kelvin K.W. Chan. (2016) Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. Journal of Oncology Practice 12:4, pages e369-e379.
Crossref
Crossref
Jagpreet Chhatwal, Michael Mathisen & Hagop Kantarjian. (2015) Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer 121:19, pages 3372-3379.
Crossref
Crossref
Scott F. HuntingtonJakub SvobodaJalpa A. Doshi. (2015) Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal of Clinical Oncology 33:13, pages 1467-1474.
Crossref
Crossref
Qiushi Chen, Turgay Ayer, Loretta J. Nastoupil, Adam C. Rose & Christopher R. Flowers. (2015) Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma. Value in Health 18:2, pages 189-197.
Crossref
Crossref
Cheng-Ping Mao, Martin R. Brovarney, Karim Dabbagh, Herbert F. Birnböck, Wolfgang F. Richter & Christopher J. Del Nagro. (2013) Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys. PLoS ONE 8:11, pages e80533.
Crossref
Crossref
Pier Luigi Zinzani, Monia Marchetti, Atto Billio, Giovanni Barosi, Angelo Michele Carella, Mario Lazzarino, Maurizio Martelli, Alessandro Rambaldi, Luigi Rigacci, Corrado Tarella, Umberto Vitolo & Sante Tura. (2013)
SIE
,
SIES
,
GITMO
revised guidelines for the management of follicular lymphoma
. American Journal of Hematology 88:3, pages 185-192.
Crossref
Crossref
Yoon Soo Kyung, Heeyoon Park & Gilho Lee. (2012) Intravesical epinephrine preserves uroplakin II expression in urinary bladder from cyclophosphamide-induced rat cystitis. Naunyn-Schmiedeberg's Archives of Pharmacology 385:8, pages 769-776.
Crossref
Crossref
Philipp W.P. Auweiler, Dirk Müller, Stephanie Stock & Andreas Gerber. (2012) Cost Effectiveness of Rituximab for Non-Hodgkinʼs Lymphoma. PharmacoEconomics 30:7, pages 537-549.
Crossref
Crossref
Erkki J. Soini, Janne A. Martikainen, Ville Vihervaara, Kim Mustonen & Tapio Nousiainen. (2012) Economic Evaluation of Sequential Treatments for Follicular Non-Hodgkin Lymphoma. Clinical Therapeutics 34:4, pages 915-925.e2.
Crossref
Crossref
Robert I. Griffiths, Michelle L. Gleeson, Joseph Mikhael & Mark D. Danese. (2012) Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare. Journal of Cancer Epidemiology 2012, pages 1-13.
Crossref
Crossref
Gillian M. Keating. (2011) Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma†. BioDrugs 25:1, pages 55-61.
Crossref
Crossref
Yoon Soo Kyung, Hee Yoon Park & Gilho Lee. (2010) Preservation of uroplakins by 2-mercaptoethanesulfonate in cyclophosphamide-induced rat cystitis. Archives of Toxicology 85:1, pages 51-57.
Crossref
Crossref
Johan de Raad, Kees van Gool, Marion Haas, Philip Haywood, Margaret Faedo, Gisselle Gallego, Sallie Pearson & Robyn Ward. (2010) Nursing Takes Time: Workload Associated With Administering Cancer Protocols. Clinical Journal of Oncology Nursing 14:6, pages 735-741.
Crossref
Crossref
Gillian M. Keating. (2010) Rituximab. Drugs 70:11, pages 1445-1476.
Crossref
Crossref
Joshua A. Ray, Emma Carr, Gavin Lewis & Robert Marcus. (2010) An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK. Value in Health 13:4, pages 346-357.
Crossref
Crossref
Fredrick Hagemeister. (2010) Rituximab for the Treatment of Non-Hodgkinʼs Lymphoma and Chronic Lymphocytic Leukaemia. Drugs 70:3, pages 261-272.
Crossref
Crossref
Ya-Chen Tina Shih, Linda S. Elting & Michael T. Halpern. (2009) Factors Associated With Immunotherapy Use Among Newly Diagnosed Cancer Patients. Medical Care 47:9, pages 948-958.
Crossref
Crossref
Seong Hoo ChoiYoungmin ByunGilho Lee. (2009) Expressions of Uroplakins in the Mouse Urinary Bladder with Cyclophosphamide-Induced Cystitis. Journal of Korean Medical Science 24:4, pages 684.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref
Crossref